Pacira BioSciences
PCRX
168 hedge funds and large institutions have $1.36B invested in Pacira BioSciences in 2018 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 58 increasing their positions, 60 reducing their positions, and 42 closing their positions.
4.17% more ownership
Funds ownership: 103.26% → 107.43% (+4.2%)
3% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 60
9% less funds holding
Funds holding: 185 → 168 (-17)
29% less capital invested
Capital invested by funds: $1.91B → $1.36B (-$550M)
36% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 42
57% less call options, than puts
Call options by funds: $12M | Put options by funds: $27.9M
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$60.7M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$36.8M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$30.9M |
| 4 |
PC
PointState Capital
New York
|
+$30.2M |
| 5 |
Jennison Associates
New York
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$23.3M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$20.3M |
| 3 |
HM
HealthCor Management
New York
|
-$17.8M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$17.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EWM
201
Evercore Wealth Management
New York
| – | -$156K | -3,409 | Closed |
|
|
QI
202
QS Investors
New York
| – | -$151K | -3,300 | Closed |
|
|
II
203
Inspire Investing
Meridian,
Idaho
| – | -$59K | -1,298 | Closed |
|
|
DSN
204
D. Scott Neal
Lexington,
Kentucky
| – | -$9K | -200 | Closed |
|
|
KF
205
Krilogy Financial
St. Louis,
Missouri
| – | -$9K | -200 | Closed |
|
206
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | +$534 | +15 | New |
|
PCRX Hedge Fund Activity: Q1 2018 in Review
168 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2018, worth a combined $1.36B — down 29% from $1.91B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of PCRX and 27 opened new positions — a net loss of 15 holders — while 60 trimmed existing stakes and 58 added.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $60.7M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $23.3M sold.
- 168 institutional investors held Pacira BioSciences (PCRX) as of Q1 2018, down from 185 in Q4 2017.
- Funds reported $1.36B of Pacira BioSciences stock for Q1 2018, down 29% quarter-over-quarter.
- 27 funds opened new Pacira BioSciences positions in Q1 2018 and 42 closed out, a net change of -15 holders.
- The largest Pacira BioSciences buyer in Q1 2018 was PFM Health Sciences, an estimated $60.7M added.
- The largest Pacira BioSciences seller in Q1 2018 was Renaissance Technologies, an estimated $23.3M sold.
Based on aggregated 13F filings for Q1 2018.